D&D Pharmatech Inc (XKRX:347850) Share Price

Company Profile

Business description
D&D Pharmatech Inc is building on a robust foundation of proprietary peptide research and strategic collaborations. The group is advancing a diverse pipeline of therapeutics for metabolic, fibrotic, and neurodegenerative diseases. The world-wide biotech company's umbrella structure comprises three U.S. subsidiaries, which include its clinical research arm responsible for conducting clinical trials for the company's pipeline, including its dual agonist (GLP-1/glucagon) for metabolic dysfunction-associated steatohepatitis (MASH).
Contact
27, Geumto-ro 80beon-gil
4th floor, Geumto-dong
Sujeong-gu, Gyeonggi-do
Seongnam-si13454
KOR
T: +82 3180197771
http://www.ddpharmatech.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
21

Recommended

We now forecast mildly better revenue growth and EPS growth, alongside more intense near-term cash flow pressure.

Eric Compton, CFA | 29 October 2026

We believe that investors are underappreciating the breadth and depth of Alphabet’s AI monetization and the rapid upcoming growth in Google Cloud.

Malik Ahmed Khan, CFA | 29 October 2026

Solid results included strong full-self driving software uptake and positive free cash flow.

Seth Goldstein, CFA | 29 October 2026

Index	Last price	Change	% Change
All Ordinaries	9,012.60	41.20	0.46%
CAC 40	7,970.00	83.04	1.05%
DAX 40	26,039.68	335.66	1.31%
Dow JONES (US)	52,342.56	132.54	-0.25%
FTSE 100	10,722.07	27.57	0.26%
HKSE	22,958.65	136.18	-0.59%
NASDAQ	26,184.72	365.13	-1.38%
Nikkei 225	64,659.47	705.28	1.10%
NZX 50 Index	13,736.85	26.68	0.19%
S&P 500	7,720.39	23.59	-0.30%
S&P/ASX 200	8,891.80	44.50	0.50%
SSE Composite Index	3,651.43	30.04	-0.82%